Neuropsychiatric risk stratification in post-stroke anxiety and depression

Abstract

Ischemic stroke is increasingly recognized not only as a cerebrovascular event but also as a neuropsychiatric condition, with up to one-third of survivors developing significant anxiety or depression. The recent study by Zhao et al published in World Journal of Psychiatry provides important mechanistic insight into how structural, inflammatory, and neuroendocrine disturbances converge to shape post-stroke emotional outcomes. By integrating neuroimaging, clinical phenotyping, and biomarker profiling in patients, the authors identify a multidimensional vulnerability architecture connecting frontal-limbic infarcts, hemispheric lateralization, and white matter disruption with elevated interleukin-6, tumor necrosis factor-alpha, and cortisol, alongside reduced IGF-1. These interacting pathways highlight neuroinflammation- and HPA-axis-driven circuit dysfunction as central processes underlying early post-stroke affective disturbances. The study advances the field by demonstrating that neural circuit injury and cross-system biological dysregulation can be quantified to form clinically meaningful risk indicators, positioning inflammatory markers, cortisol rhythms, and lesion topology as potential early screening tools. Clinically, it underscores the need for integrated neuropsychiatric assessment and timely interventions targeting both biological and psychosocial pathways in the acute recovery window. Future translational work combining longitudinal imaging with biomarker panels may enable precision risk stratification and personalized prevention strategies for post-stroke anxiety and depression.

Key Words: Stroke; Anxiety; Depression; Neuroinflammation; Risk stratification; Neuropsychiatric outcomes; Post-stroke care

Core Tip: Anxiety and depression following stroke remain under-recognized contributors to long-term disability. Emerging evidence suggests these symptoms reflect quantifiable neurobiological disruptions rather than secondary reactions to impairment. This editorial argues that neuropsychiatric risk stratification—integrating lesion characteristics, neuroinflammatory biomarkers, autonomic indices, and early behavioral markers—should become a routine component of post-stroke management.

This editorial refers to "Risk factors and early identification markers for post-ischemic stroke anxiety and depression" by Zhao et al, 2026; https://doi.org/10.5498/wjp.v16.i1.113104.

---

INTRODUCTION

Stroke remains one of the leading causes of death and disability worldwide and produces a wide range of neurological consequences that extend beyond motor deficits and cognitive impairment[1]. While post-stroke depression (PSD) and post-stroke anxiety (PSA) are among the most common neuropsychiatric complications, affecting up to 33% and 25% of survivors, respectively, clinical pathways still largely prioritize physical rehabilitation, thromboembolic prevention, and secondary stroke prevention. The emotional and psychological dimensions of recovery are frequently treated as downstream issues rather than integral components of neurological health[2].

This imbalance persists despite mounting evidence that neuropsychiatric outcomes independently predict mortality, rehospitalization, caregiver burden, and long-term functional independence[3]. Patients with PSD or PSA demonstrate slower improvements in activities of daily living, reduced engagement in rehabilitation, poorer quality of life, and higher rates of recurrent vascular events[4]. Yet systematic screening and risk prediction remain inconsistent across clinical settings.

A key reason is that emotional symptoms have historically been conceptualized as reactive responses to disability. However, contemporary research increasingly demonstrates that stroke-induced alterations in limbic circuitry, inflammatory cascades[5], white matter connectivity, and autonomic regulation play mechanistic roles in the onset of anxiety and depression[6]. The recent observational cohort study by Zhao et al[7] published in World Journal of Psychiatry offers compelling evidence that neurobiological signatures present within days of stroke predict affective trajectories months later. This shifts the field toward a model where early neuropsychiatric risk can be quantified, monitored, and mitigated.

INTERPRETING THE STUDY: NEURAL NETWORK DISRUPTION AND AFFECTIVE OUTCOMES

The recent study by Zhao et al[7] provides a compelling framework for understanding how acute cerebrovascular injury disrupts large-scale neural networks and initiates a cascade of neurobiological changes that ultimately manifest as PSA and PSD. Drawing from a multicenter prospective cohort of patients with acute ischemic stroke, the authors examined a combination of structural imaging markers, white matter tract integrity, neuroinflammatory indicators, and autonomic parameters to determine which early physiological disruptions best predicted neuropsychiatric outcomes at 3- and 6-month.

Importantly, the neurobiological patterns identified by Zhao et al[7] do not emerge in isolation but rather align closely with a broader body of work in affective neuroscience and brain connectomics. Extensive prior literature has described a distributed “depression network” encompassing the prefrontal cortex[8], anterior cingulate, insula, amygdala, and related limbic-thalamo-cortical circuits, in which disrupted connectivity rather than focal damage alone drives affective symptomatology[9]. Lesion network mapping studies and functional connectivity analyses across diverse neurological and psychiatric populations have consistently shown that damage to nodes within this network confers vulnerability to depression and anxiety. In this context, the findings by Zhao et al[7] can be viewed as a clinically grounded validation of these established models within the acute ischemic stroke population, reinforcing the concept that post-stroke affective disturbances reflect network-level dysfunction rather than idiosyncratic or isolated lesion effects.

Consistent with current theories of network-based brain dysfunction, the study demonstrates that focal lesions in the insula, anterior cingulate cortex, ventromedial prefrontal cortex, and limbic-thalamo-cortical pathways are strongly associated with affective symptoms[10]. Reductions in fractional anisotropy within the uncinate fasciculus and cingulum bundle were significantly correlated with depression severity, while disruption of amygdala-prefrontal connectivity was linked to heightened anxiety[11]. These associations highlight that affective symptoms reflect not only psychosocial distress but also quantifiable disconnection of circuits governing emotion regulation, threat appraisal, and interoceptive awareness[12].

Multivariate analysis revealed that injury to fronto-limbic tracts and early elevations in inflammatory biomarkers, particularly interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), were independently associated with the development of moderate-to-severe depressive symptoms, whereas reduced heart rate variability and right-insular lesions were predictive of persistent anxiety. Elevated C-reactive protein (CRP) and a blunted cortisol awakening response were also associated with greater neuropsychiatric symptom burden. These findings support the notion that early post-stroke affective states represent a convergence of structural disconnection, neuroimmune activation, and impaired autonomic regulation.

Importantly, Zhao et al[7] incorporated standardized neuropsychiatric assessments, including the Hospital Anxiety and Depression Scale (HADS) and structured diagnostic interviews, which lend empirical rigor to their observations. Neurochemical assays further revealed imbalances in monoaminergic systems (serotonin and dopamine) and increased glutamatergic excitotoxicity, aligning with models of inflammation-driven neurotransmitter disruption. The authors propose a framework in which disrupted neural connectivity, neuroinflammatory signaling, and autonomic dysregulation interact to influence mood, cognition, and affective reactivity, situating PSA and PSD as clinically relevant indicators of global neural vulnerability.

While the findings by Zhao et al[7] significantly strengthen the evidence linking acute neurobiological disruption to downstream psychiatric symptoms, it remains important to consider potential confounding factors. Many of the conditions that accompany or precipitate stroke, such as metabolic syndrome, chronic inflammation, sleep disturbances, or pre-stroke psychological stress, may themselves predispose individuals to anxiety or depression through mechanisms independent of acute neural injury[13,14]. This complicates the attribution of early affective symptoms solely to stroke-related neurobiology. Future studies should seek to disentangle these influences by comparing neuropsychiatric trajectories across patients with equivalent vascular risk profiles but differing degrees of neural network disruption, while also adjusting for baseline mental health status and systemic comorbidities.

THE MISSED OPPORTUNITY IN STROKE CARE

Although PSA and PSD are now recognized as major determinants of long-term functional recovery, current stroke care pathways still underemphasize systematic neuropsychiatric risk assessment[13]. Most stroke guidelines primarily target neurological stability, focusing on blood pressure thresholds, reperfusion management, secondary prevention, and rehabilitation initiation while dedicating minimal attention to structured psychiatric evaluation[14]. Even widely implemented protocols such as the post-stroke complication bundles emphasize dysphagia screening, pressure injury prevention, early mobilization, and thromboembolism prophylaxis but offer no practical framework for stratifying psychiatric risk beyond recommending “routine mood assessment” at follow-up visits[15].

Screening that is performed during hospitalization is often limited to brief tools, such as the Patient Health Questionnaire-2 or simple affect observation, which are insufficient for identifying high-risk individuals with subtle prodromal symptoms or fluctuating emotional states. Anxiety, despite being as prevalent as depression after stroke, is rarely evaluated at all in the acute period, despite mounting data demonstrating that early anxiety symptoms predict poorer cognitive recovery, reduced participation in rehabilitation, and higher rates of long-term disability. In practice, therefore, most stroke survivors are discharged without receiving a formal psychiatric risk profile, representing a critical missed opportunity for early intervention[16].

Implementation gaps further widen the problem. Studies consistently show that between 40% and 60% of stroke inpatients receive no standardized depression screening, and fewer than 15% are evaluated for anxiety using validated instruments during the acute hospitalization or subacute rehabilitation phase[17]. Psychiatric referrals remain largely reactive, triggered only when symptoms become clinically disruptive. Emerging pilot programs integrating neuropsychology or psychiatric consultation early in the stroke timeline have demonstrated improvements in diagnostic accuracy and rehabilitation engagement, yet they remain underutilized due to staffing limitations and the persistent misconception that neuropsychiatric symptoms are inevitable or self-limited[18].

This under recognition is particularly concerning because PSA and PSD are not merely a psychological sequela but a potential indicator of underlying cerebral stress, network dysfunction, and neuroinflammatory activity[19]. Early affective changes often map onto stroke lesion characteristics, perfusion deficits, and autonomic dysregulation. Physiological domains that clinicians routinely monitor but rarely interpret in psychiatric terms. As highlighted in recent neuroimaging-mechanistic studies, mood and anxiety symptoms may emerge before overt cognitive decline or functional regression, serving as early warning signs of fragile neural circuits or maladaptive post-stroke plasticity.

Integrating structured neuropsychiatric monitoring into standard stroke care, particularly during the first 72 hours, when cerebral remodeling and autonomic instability are most dynamic, may therefore provide critical insights that complement neurological and hemodynamic assessment. A risk-stratification protocol that incorporates lesion loci, white-matter disconnection patterns, premorbid psychiatric history, inflammatory markers, autonomic function indices, and early mood-behavioral observations could help clinicians identify vulnerable patients earlier, tailor rehabilitation intensity, and initiate preventive psychotherapeutic or pharmacologic interventions[20].

Without this integration, patients continue to face preventable emotional distress and functional decline, while clinicians miss the opportunity to leverage neuropsychiatric symptoms as meaningful indicators of cerebral vulnerability and recovery potential.

A CALL TO RECALIBRATE CLINICAL PRIORITIES

Emerging evidence underscores the need to expand how we monitor and manage PSA and PSD. If neuropsychiatric complications such as anxiety and depression are linked to lesion location, cerebral network disruption, autonomic imbalance, or neuroinflammation, then early and systematic assessment of mood and affective state should become an integral component of stroke care. Just as blood pressure and perfusion metrics are trended to guide therapy, early changes in mood or anxiety could serve as dynamic indicators of cerebral vulnerability and functional prognosis. Incorporating neuropsychiatric monitoring into standard post-stroke protocols does not detract from current priorities; it supplements them, providing a more holistic approach to recovery[21].

Standardized psychological screening instruments, including the HADS, the Patient Health Questionnaire-9, and the Generalized Anxiety Disorder Scale-7[22], remain foundational tools for identifying early affective disturbances. Expanding their use beyond isolated time points to include repeated or longitudinal assessment during hospitalization and early rehabilitation may improve sensitivity to evolving emotional trajectories. In parallel, emerging digital platforms and structured bedside assessments could facilitate more continuous cognitive-emotional monitoring, particularly in patients with fluctuating symptoms or limited insight[23].

Importantly, the clinical translation of neuropsychiatric risk stratification must be aligned with real-world resource constraints. Although advanced measures such as diffusion tensor imaging, inflammatory cytokine profiling (e.g., IL-6 and TNF-α), and detailed autonomic indices provide valuable mechanistic insight, their routine acquisition within the first 72 hours after stroke is often limited by cost, availability, and workflow demands, particularly outside tertiary care centers[24]. A pragmatic, tiered approach may therefore be more feasible in clinical practice. In this model, standardized psychological screening serves as a first-line assessment for all patients, while more advanced neurobiological measures are selectively applied to individuals at higher risk, such as those with insular or frontal lesions, discordance between emotional symptoms and neurological deficits, or early behavioral features suggestive of neuropsychiatric vulnerability. This stratified strategy preserves scientific rigor while enhancing clinical feasibility and scalability across diverse stroke care settings.

Beyond behavioral assessments, biomarkers reflecting neuroinflammation may provide insight into susceptibility to PSA and PSD. Cytokines such as IL-6, TNF-α, and CRP are frequently elevated after stroke and have been associated with both lesion severity and neuropsychiatric symptom burden. While routine cytokine monitoring is not yet standard practice, these findings suggest that inflammatory markers could help identify high-risk patients, enabling targeted interventions and early preventive strategies[25]. Future research should explore their role in risk stratification and clinical decision-making for post-stroke care.

Although early detection of PSA and PSD is crucial, effective prevention and intervention remain challenging. Evidence regarding pharmacologic and psychosocial interventions is mixed, and implementation of multicomponent programs is often constrained by limited resources in acute and subacute stroke units. These challenges highlight the need for research on practical, scalable approaches to integrate neuropsychiatric monitoring and early intervention into existing workflows. Potential strategies include optimizing sleep hygiene, encouraging early mobilization, providing access to sensory and cognitive aids, and involving family members in structured reorientation and psychosocial support during recovery.

CONCLUSION

As survival rates improve and stroke systems of care mature, the definition of recovery must expand beyond motor and cognitive domains to include emotional and psychological health. Anxiety and depression after stroke are not inevitable consequences but modifiable outcomes shaped by neurobiology, neuroinflammation, and early clinical management. Neuropsychiatric risk stratification represents an actionable, evidence-based strategy to improve long-term functional recovery. Neurologists, psychiatrists, rehabilitation specialists, and neuroimaging scientists must work together to refine predictive models, develop feasible workflows, and integrate emotional monitoring into routine stroke care. Protecting the mind should begin at the same moment we work to preserve the brain.